Comparison of the effects of brimonidine 0.2% and timolol 0.5% on retinal nerve fiber layer thickness in ocular hypertensive patients: a prospective, unmasked study
- PMID: 16386089
- DOI: 10.1089/jop.2005.21.475
Comparison of the effects of brimonidine 0.2% and timolol 0.5% on retinal nerve fiber layer thickness in ocular hypertensive patients: a prospective, unmasked study
Abstract
Aims: The aim of this study was to compare the effects of brimonidine and timolol on retinal nerve fiber layer (RNFL) thickness in ocular hypertensive patients.
Methods: This was a prospective, comparative, and unmasked study. For 12 months, 38 eyes of 19 patients with primary open-angle glaucoma received brimonidine tartrate 0.2%, and 40 eyes of 20 patients received timolol maleate 0.5%. Intraocular pressure (IOP) was measured every 2 months, and RNFL thickness was assessed using Scanning laser polarimetry (GDx) at baseline and at 12 months.
Results: Mean IOP reduction was similar in both groups. Within each treatment group, the RNFL thickness for ellipse average (P = 0.004), superior (P = 0.035), temporal (P = 0.003), inferior (P < 0.0001), and nasal averages (P = 0.044) were significantly decreased from baseline in timolol at 12 months. However, the RNFL thickness for ellipse average and four quadrants showed no significant change from baseline in brimonidine. The between-group difference in RNFL change showed a significant reduction for ellipse average (P = 0.02), temporal (P = 0.005), and inferior averages (P = 0.016) following timolol therapy, as compared to brimonidine.
Conclusions: There appear to be less progression for RNFL damage following brimonidine 0.2% therapy compared to timolol 0.5% in ocular hypertensive patients over 1 year. This finding does not correlate with IOP reduction.
Similar articles
-
Twice-daily 0.2% brimonidine-0.5% timolol fixed-combination therapy vs monotherapy with timolol or brimonidine in patients with glaucoma or ocular hypertension: a 12-month randomized trial.Arch Ophthalmol. 2006 Sep;124(9):1230-8. doi: 10.1001/archopht.124.9.1230. Arch Ophthalmol. 2006. PMID: 16966616 Clinical Trial.
-
Comparison of the efficacy and safety of dorzolamide 2% when added to brimonidine 0.2% or timolol maleate 0.5% in patients with primary open-angle glaucoma.J Ocul Pharmacol Ther. 2005 Feb;21(1):68-74. doi: 10.1089/jop.2005.21.68. J Ocul Pharmacol Ther. 2005. PMID: 15718830 Clinical Trial.
-
An eight-week, multicentric, randomized, interventional, open-label, phase 4, parallel comparison of the efficacy and tolerability of the fixed combination of timolol maleate 0.5%/brimonidine tartrate 0.2% versus fixed combination of timolol maleate 0.5%/dorzolamide 2% in patients with elevated intraocular pressure.J Glaucoma. 2008 Dec;17(8):674-9. doi: 10.1097/IJG.0b013e318168f008. J Glaucoma. 2008. PMID: 19092465 Clinical Trial.
-
Topical brimonidine 0.2%/timolol 0.5% ophthalmic solution: in glaucoma and ocular hypertension.Drugs Aging. 2006;23(9):753-61. doi: 10.2165/00002512-200623090-00005. Drugs Aging. 2006. PMID: 17020399 Review.
-
Efficacy, safety, and current applications of brimonidine.Expert Opin Drug Saf. 2008 Nov;7(6):795-9. doi: 10.1517/17425250802457609. Expert Opin Drug Saf. 2008. PMID: 18983225 Review.
Cited by
-
Fixed combination of topical brimonidine 0.2% and timolol 0.5% for glaucoma and uncontrolled intraocular pressure.Clin Ophthalmol. 2008 Sep;2(3):545-55. doi: 10.2147/opth.s3840. Clin Ophthalmol. 2008. PMID: 19668752 Free PMC article.
-
Neuroprotection in Glaucoma.J Ophthalmic Vis Res. 2016 Apr-Jun;11(2):209-20. doi: 10.4103/2008-322X.183923. J Ophthalmic Vis Res. 2016. PMID: 27413504 Free PMC article. Review.
-
Neuroprotective Strategies for Retinal Ganglion Cell Degeneration: Current Status and Challenges Ahead.Int J Mol Sci. 2020 Mar 25;21(7):2262. doi: 10.3390/ijms21072262. Int J Mol Sci. 2020. PMID: 32218163 Free PMC article. Review.
-
A longitudinal comparison in cynomolgus macaques of the effect of brimonidine on optic nerve neuropathy using diffusion tensor imaging magnetic resonance imaging and spectral domain optical coherence tomography.Heliyon. 2021 Apr 6;7(4):e06701. doi: 10.1016/j.heliyon.2021.e06701. eCollection 2021 Apr. Heliyon. 2021. PMID: 33898826 Free PMC article.
-
Brimonidine in the treatment of glaucoma and ocular hypertension.Ther Clin Risk Manag. 2006 Dec;2(4):337-46. doi: 10.2147/tcrm.2006.2.4.337. Ther Clin Risk Manag. 2006. PMID: 18360646 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical